Natera Inc (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 794 Shares

Natera Inc (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 794 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $24.79, for a total value of $19,683.26. Following the completion of the transaction, the chief executive officer now directly owns 9,919 shares in the company, valued at approximately $245,892.01. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

  • On Friday, March 22nd, Steven Leonard Chapman sold 384 shares of Natera stock. The shares were sold at an average price of $20.20, for a total value of $7,756.80.

NTRA traded down $0.61 during mid-day trading on Friday, hitting $24.55. 14,325 shares of the stock were exchanged, compared to its average volume of 564,092. Natera Inc has a 1-year low of $11.08 and a 1-year high of $29.62. The company has a current ratio of 1.85, a quick ratio of 1.73 and a debt-to-equity ratio of 20.88. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -11.48 and a beta of 1.43.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, May 9th. The medical research company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.05. Natera had a negative return on equity of 699.31% and a negative net margin of 49.33%. The firm had revenue of $66.82 million for the quarter, compared to analyst estimates of $66.40 million. On average, research analysts forecast that Natera Inc will post -2.17 earnings per share for the current year.

Several equities analysts have recently commented on the company. BidaskClub lowered Natera from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Zacks Investment Research raised Natera from a “sell” rating to a “hold” rating in a research note on Saturday, April 20th. Finally, Piper Jaffray Companies increased their target price on Natera from $23.00 to $28.00 and gave the stock an “overweight” rating in a research note on Monday. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Natera has a consensus rating of “Buy” and an average target price of $28.25.

Institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 209.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 160,128 shares of the medical research company’s stock worth $3,833,000 after acquiring an additional 108,310 shares during the last quarter. Teachers Advisors LLC lifted its holdings in shares of Natera by 519.9% in the 3rd quarter. Teachers Advisors LLC now owns 357,757 shares of the medical research company’s stock worth $8,565,000 after acquiring an additional 300,047 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Natera by 52.7% in the 4th quarter. Rhumbline Advisers now owns 44,091 shares of the medical research company’s stock worth $616,000 after acquiring an additional 15,220 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in shares of Natera by 6.7% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 11,485 shares of the medical research company’s stock worth $160,000 after acquiring an additional 717 shares during the last quarter. Finally, Tygh Capital Management Inc. lifted its holdings in shares of Natera by 18.0% in the 4th quarter. Tygh Capital Management Inc. now owns 414,726 shares of the medical research company’s stock worth $5,790,000 after acquiring an additional 63,155 shares during the last quarter. 80.32% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Riverton Roll and is the property of of Riverton Roll. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://rivertonroll.com/news/2019/06/14/natera-inc-nasdaqntra-ceo-steven-leonard-chapman-sells-794-shares.html.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Story: Investing in Blue-Chip Stocks

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.